MNMD Insider Trading
Insider Ownership Percentage: 2.26%
Insider Buying (Last 12 Months): $24,085.00
Insider Selling (Last 12 Months): $749,479.40
Mind Medicine (MindMed) Insider Trading History Chart
This chart shows the insider buying and selling history at Mind Medicine (MindMed) by year and by quarter.
Skip ChartChart Data in Insider Trading History Table
Mind Medicine (MindMed) Share Price & Price History
Current Price: $5.43
Price Change: ▲ Price Increase of +0.29 (5.64%)
As of 04/11/2025 05:00 PM ET
Mind Medicine (MindMed) Insider Trading History
Mind Medicine (MindMed) Institutional Trading History
Data available starting January 2016
Mind Medicine (MindMed) Inc., a clinical stage biopharmaceutical company, develops novel products to treat brain health disorders. The company's lead product candidates include MM-120, which is in phase 2 for the treatment of generalized anxiety disorder and attention deficit hyperactivity disorder; and MM-402, a R-enantiomer of 3,4-methylenedioxymethamphetamine, which is in phase I clinical trials for the treatment of core symptoms of autism spectrum disorder. Mind Medicine (MindMed) Inc. is headquartered in New York, New York.
Read More on Mind Medicine (MindMed)
Volume
604,202 shs
Average Volume
1,401,941 shs
Market Capitalization
$409.25 million
P/E Ratio
N/A
Dividend Yield
N/A
Beta
2.54
Who are the company insiders with the largest holdings of Mind Medicine (MindMed)?
Who are the major institutional investors of Mind Medicine (MindMed)?
Which major investors are buying Mind Medicine (MindMed) stock?
Within the last quarter, MNMD stock was acquired by institutional investors including:
- Rhumbline Advisers
In the previous year, these company insiders have bought Mind Medicine (MindMed) stock:
- Robert Barrow (CEO)
- Daniel Karlin (Insider)
Learn More investors buying Mind Medicine (MindMed) stock.